|
1
|
Ke L: Mortality and incidence trends from
esophagus cancer in selected geographic areas of China circa
1970–90. Int J Cancer. 102:271–274. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parkin DM, Bray FI and Devesa SS: Cancer
burden in the year 2000. The global picture. Eur J Cancer. 37(Suppl
8): S4–66. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A1, Bray F, Center MM, Ferlay J,
Ward E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yen CC, Chen YJ, Chen JT, Hsia JY, Chen
PM, Liu JH, Fan FS, Chiou TJ, Wang WS and Lin CH: Comparative
genomic hybridization of esophageal squamous cell carcinoma:
Correlations between chromosomal aberrations and disease
progression/prognosis. Cancer. 92:2769–2777. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kwong D, Lam A, Guan X, Law S, Tai A, Wong
J and Sham J: Chromosomal aberrations in esophageal squamous cell
carcinoma among Chinese: Gain of 12p predicts poor prognosis after
surgery. Hum Pathol. 35:309–316. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qin YR, Wang LD, Kwong D, Gao SS, Guan XY,
Zhuang ZH, Fan ZM, Deng W and Hu L: Comparative genomic
hybridization: The profile of chromosomal imbalances in esophageal
squamous cell carcinoma. Zhonghua Bing Li Xue Za Zhi. 34:80–83.
2005.In Chinese. PubMed/NCBI
|
|
7
|
Ogasawara S, Maesawa C, Tamura G and
Satodate R: Frequent microsatellite alterations on chromosome 3p in
esophageal squamous cell carcinoma. Cancer Res. 55:891–894.
1995.PubMed/NCBI
|
|
8
|
Dammann R, Li C, Yoon JH, Chin PL, Bates S
and Pfeifer GP: Epigenetic inactivation of a RAS association domain
family protein from the lung tumour suppressor locus 3p21.3. Nat
Genet. 25:315–319. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ji L, Nishizaki M, Gao B, Burbee D, Kondo
M, Kamibayashi C, Xu K, Yen N, Atkinson EN, Fang B, et al:
Expression of several genes in the human chromosome 3p21.3
homozygous deletion region by an adenovirus vector results in tumor
suppressor activities in vitro and in vivo. Cancer Res.
62:2715–2720. 2002.PubMed/NCBI
|
|
10
|
Daigo Y, Nishiwaki T, Kawasoe T, Tamari M,
Tsuchiya E and Nakamura Y: Molecular cloning of a candidate tumor
suppressor gene, DLC1, from chromosome 3p21.3. Cancer Res.
59:1966–1972. 1999.PubMed/NCBI
|
|
11
|
Fu L, Qin YR, Xie D, Hu L, Kwong DL,
Srivastava G, Tsao SW and Guan XY: Characterization of a novel
tumor-suppressor gene PLC delta 1 at 3p22 in esophageal squamous
cell carcinoma. Cancer Res. 67:10720–10726. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Castro-Rivera E, Ran S, Thorpe P and Minna
JD: Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast
cancer, whereas VEGF165 antagonizes this effect. Proc
Natl Acad Sci USA. 101:11432–11437. 2004. View Article : Google Scholar
|
|
13
|
Tomizawa Y, Sekido Y, Kondo M, Gao B,
Yokota J, Roche J, Drabkin H, Lerman MI, Gazdar AF and Minna JD:
Inhibition of lung cancer cell growth and induction of apoptosis
after reexpression of 3p21.3 candidate tumor suppressor gene
SEMA3B. Proc Natl Acad Sci USA. 98:13954–13959. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tse C, Xiang RH, Bracht T and Naylor SL:
Human Semaphorin 3B (SEMA3B) located at chromosome 3p21.3
suppresses tumor formation in an adenocarcinoma cell line. Cancer
Res. 62:542–546. 2002.PubMed/NCBI
|
|
15
|
Tischoff I, Markwarth A, Witzigmann H,
Uhlmann D, Hauss J, Mirmohammadsadegh A, Wittekind C, Hengge UR and
Tannapfel A: Allele loss and epigenetic inactivation of 3p21.3 in
malignant liver tumors. Int J Cancer. 115:684–689. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qin YR1, Tang H, Xie F, Liu H, Zhu Y, Ai
J, Chen L, Li Y, Kwong DL, Fu L and Guan XY: Characterization of
tumor-suppressive function of SOX6 in human esophageal squamous
cell carcinoma. Clin Cancer Res. 17:46–55. 2011. View Article : Google Scholar
|
|
17
|
Shimada Y, Imamura M, Wagata T, Yamaguchi
N and Tobe T: Characterization of 21 newly established esophageal
cancer cell lines. Cancer. 69:277–284. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xie D, Sham JS, Zeng WF, Lin HL, Che LH,
Wu HX, Wen JM, Fang Y, Hu L and Guan XY: Heterogeneous expression
and association of beta-catenin, p16 and c-myc in multistage
colorectal tumorigenesis and progression detected by tissue
microarray. Int J Cancer. 107:896–902. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brown RS and Wahl RL: Overexpression of
Glut-1 glucose transporter in human breast cancer. An
immunohistochemical study. Cancer. 72:2979–2985. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zou Y, Stoeckli E, Chen H and
Tessier-Lavigne M: Squeezing axons out of the gray matter: A role
for slit and semaphorin proteins from midline and ventral spinal
cord. Cell. 102:363–375. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Loginov VI, Dmitriev AA, Senchenko VN,
Pronina IV, Khodyrev DS, Kudryavtseva AV, Krasnov GS, Gerashchenko
GV, Chashchina LI, Kazubskaya TP, et al: Tumor suppressor function
of the SEMA3B gene in human lung and renal cancers. PLoS One.
10:e01233692015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Senchenko VN, Liu J, Loginov W, Bazov I,
Angeloni D, Seryogin Y, Ermilova V, Kazubskaya T, Garkavtseva R,
Zabarovska VI, et al: Discovery of frequent homozygous deletions in
chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast
carcinomas. Oncogene. 23:5719–5728. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ito M, Ito G, Kondo M, Uchiyama M, Fukui
T, Mori S, Yoshioka H, Ueda Y, Shimokata K and Sekido Y: Frequent
inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter
hypermethylation and allele loss in non-small cell lung cancer.
Cancer Lett. 225:131–139. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Loginov VI, Khodyrev DS, Pronina IV,
Maliukova AV, Kazubskaia TP, Ermilova VD, Gar'kavtseva RF,
Zabarovskiĭ ER and Braga EA: Two CpG-islands of SEMA3B gene:
Methylation in clear cell renal cell carcinoma. Mol Biol.
43:1088–1092. 2009.In Russian. View Article : Google Scholar
|
|
25
|
Chen R, Zhuge X, Huang Z, Lu D, Ye X, Chen
C, Yu J and Lu G: Analysis of SEMA3B methylation and expression
patterns in gastric cancer tissue and cell lines. Oncol Rep.
31:1211–1218. 2014.PubMed/NCBI
|
|
26
|
Wang K, Ling T, Wu H and Zhang J:
Screening of candidate tumor-suppressor genes in 3p21.3 and
investigation of the methylation of gene promoters in oral squamous
cell carcinoma. Oncol Rep. 29:1175–1182. 2013.PubMed/NCBI
|
|
27
|
Kuroki T, Trapasso F, Yendamuri S,
Matsuyama A, Alder H, Williams NN, Kaiser LR and Croce CM: Allelic
loss on chromosome 3p21.3 and promoter hypermethylation of
semaphorin 3B in non-small cell lung cancer. Cancer Res.
63:3352–3355. 2003.PubMed/NCBI
|
|
28
|
Castro-Rivera E, Ran S, Brekken RA and
Minna JD: Semaphorin 3B inhibits the phosphatidylinositol
3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer
cells. Cancer Res. 68:8295–8303. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dudek H, Datta SR, Franke TF, Birnbaum MJ,
Yao R, Cooper GM, Segal RA, Kaplan DR and Greenberg ME: Regulation
of neuronal survival by the serine-threonine protein kinase Akt.
Science. 275:661–665. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kennedy SG, Wagner AJ, Conzen SD, Jordán
J, Bellacosa A, Tsichlis PN and Hay N: The PI 3-kinase/Akt
signaling pathway delivers an anti-apoptotic signal. Genes Dev.
11:701–713. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Manning BD and Cantley LC: AKT/PKB
signaling: Navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Carnero A, Blanco-Aparicio C, Renner O,
Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer,
therapeutic implications. Curr Cancer Drug Targets. 8:187–198.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Janku F, Stewart DJ and Kurzrock R:
Targeted therapy in non-small-cell lung cancer - is it becoming a
reality? Nat Rev Clin Oncol. 7:401–414. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Reungwetwattana T, Weroha SJ and Molina
JR: Oncogenic pathways, molecularly targeted therapies, and
highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar
|
|
35
|
Datta SR, Dudek H, Tao X, Masters S, Fu H,
Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples
survival signals to the cell-intrinsic death machinery. Cell.
91:231–241. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo
P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME: Akt
promotes cell survival by phosphorylating and inhibiting a Forkhead
transcription factor. Cell. 96:857–868. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cardone MH, Roy N, Stennicke HR, Salvesen
GS, Franke TF, Stanbridge E, Frisch S and Reed JC: Regulation of
cell death protease caspase-9 by phosphorylation. Science.
282:1318–1321. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sherr CJ and Weber JD: The ARF/p53
pathway. Curr Opin Genet Dev. 10:94–99. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shin I, Yakes FM, Rojo F, Shin NY, Bakin
AV, Baselga J and Arteaga CL: PKB/Akt mediates cell-cycle
progression by phosphorylation of p27Kip1 at threonine
157 and modulation of its cellular localization. Nat Med.
8:1145–1152. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
40
|
Diehl JA, Cheng M, Roussel MF and Sherr
CJ: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis
and subcellular localization. Genes Dev. 12:3499–3511. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhou BP, Liao Y, Xia W, Spohn B, Lee MH
and Hung MC: Cytoplasmic localization of p21Cip1/WAF1 by
Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat
Cell Biol. 3:245–252. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
42
|
Oliveira CS, de Bock CE, Molloy TJ,
Sadeqzadeh E, Geng XY, Hersey P, Zhang XD and Thorne RF: Macrophage
migration inhibitory factor engages PI3K/Akt signalling and is a
prognostic factor in metastatic melanoma. BMC Cancer. 14:6302014.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rolny C, Capparuccia L, Casazza A, Mazzone
M, Vallario A, Cignetti A, Medico E, Carmeliet P, Comoglio PM and
Tamagnone L: The tumor suppressor semaphorin 3B triggers a
prometastatic program mediated by interleukin 8 and the tumor
microenvironment. J Exp Med. 205:1155–1171. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami
S, Stanley ER, Segall JE, Pollard JW and Condeelis J: Direct
visualization of macrophage-assisted tumor cell intravasation in
mammary tumors. Cancer Res. 67:2649–2656. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nguyen H, Ivanova VS, Kavandi L, Rodriguez
GC, Maxwell GL and Syed V: Progesterone and 1,25-dihydroxyvitamin
D3 inhibit endometrial cancer cell growth by
upregulating semaphorin 3B and semaphorin 3F. Molecular cancer
research. Mol Cancer Res. 9:1479–1492. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tunuguntla R, Ripley D, Sang QX and
Chegini N: Expression of matrix metalloproteinase-26 and tissue
inhibitors of metalloproteinases TIMP-3 and -4 in benign
endometrium and endometrial cancer. Gynecol Oncol. 89:453–459.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Staton CA, Shaw LA, Valluru M, Hoh L, Koay
I, Cross SS, Reed MW and Brown NJ: Expression of class 3
semaphorins and their receptors in human breast neoplasia.
Histopathology. 59:274–282. 2011. View Article : Google Scholar : PubMed/NCBI
|
